ArticleClinics in dermatology
Pityriasis rosea, pityriasis rosea-like eruptions, and herpes zoster in the setting of COVID-19 and COVID-19 vaccination.
Article in Clinics in dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- New Insights into Infectious Skin and Mucosal Diseases: Translating Epidemiological Shifts into Tailored Clinical Practice.Journal of clinical medicine · 2026Article
- Shingles: 10-year evolution of patient characteristics, clinical manifestations, therapeutic approach and complications.Skin health and disease · 2026Article
- Beyond the Herald Patch: Exploring the Complex Landscape of Pityriasis Rosea.American journal of clinical dermatology · 2025Review
- Herald Patch as the Only Evidence of Pityriasis Rosea: Clinical, Laboratory and Pathogenetic Features.Viruses · 2025Observational
- Recent Advances in Inflammatory Skin Diseases: Future Research on Viral Reactivations and Vaccine Improvement.Journal of clinical medicine · 2024Article
- Comparative Efficacy of Different Pharmacological Treatments for Pityriasis Rosea: A Network Meta-Analysis.Journal of clinical medicine · 2024Review
- Pityriasis rosea-like drug eruption secondary to deucravacitinib.JAAD case reports · 2024Article
- Pityriasis Rosea and Pityriasis Rosea-like Eruption Following COVID-19 Vaccinations: Case Series from Oman.Oman medical journal · 2023Article
- Review
- Cutaneous Manifestation in COVID-19: A Lesson Over 2 Years Into the Pandemic.Clinical medicine & research · 2023Review
- Eosinophil-rich linear IgA bullous dermatosis induced by mRNA COVID-19 booster vaccine.Journal of cutaneous pathology · 2023Article
- Pityriasis rosea and pityriasis rosea-like eruptions after COVID-19 vaccines.JAAD international · 2022Article
- The significance of investigating clinical, histopathologic and virological features in pityriasis rosea and pityriasis rosea-like eruptions following COVID-19 vaccinations.Dermatologic therapy · 2022Article
- Pityriasis rosea during COVID-19: Pathogenesis, diagnosis, and treatment.Journal of medical virology · 2022Article
- COVID-19-associated pityriasis rosea in children: Case report and literature review.Clinical case reports · 2022Article
- The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review.Clinical, cosmetic and investigational dermatology · 2022Review
- Pityriasis Rosea Presenting as Psoriasiform Plaque.Indian journal of dermatologyArticle
- Pityriasis rosea and pityriasis rosea-like eruption: The distinction is relevant for diagnostic and prognostic reasons.Journal of family & community medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pityriasis rosea (PR), PR-like eruptions (PR-LE), and herpes zoster have been frequently reported during the COVID-19 pandemic and following COVID-19 vaccination. PR is a self-limiting exanthematous disease and herpes zoster is a treatable condition; therefore, their occurrence does not require discontinuation of the vaccination schedule. PR-LE is a hypersensitivity reaction and is, therefore, less predictable in its course. In the case of a booster dose, the clinical manifestation may not recur, may be different from PR-LE, or may present with systemic symptoms; however, in the case of PR-LE, the possibility of mild and predominantly cutaneous adverse events should not discourage all eligible candidates from receiving and completing the COVID-19 vaccination program, as such adverse reactions represent a small risk considering the possible severe and fatal outcome of COVID-19. We emphasize the relevance of looking for any viral reactivation in patients infected with SARS-CoV-2 who have skin eruptions. The search for viral reactivations could be useful not only for distinguishing between PR and PR-LE but also because viral reactivations may contribute to a patient's systemic inflammation and influence the course of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.